News
The firm is evaluating its radiopharmaceutical imaging agent targeting PDGFRα, TLX300-CDx, in advanced or metastatic soft tissue sarcoma. Epicrispr Biotechnologies Raises $68M in Series B Financing, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback